The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Nov. 25, 2019
Applicant:
City of Hope, Duarte, CA (US);
Inventors:
Don J. Diamond, Glendora, CA (US);
Edwin Manuel, San Diego, CA (US);
Assignee:
CITY OF HOPE, Duarte, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2020.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C12N 1/20 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1138 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); C12N 1/20 (2013.01); C12N 15/1136 (2013.01); C12N 15/1137 (2013.01); C12Y 113/11052 (2013.01); C12Y 305/03001 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/32 (2013.01); C12N 2330/50 (2013.01); Y02A 50/30 (2018.01);
Abstract
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include astrain comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth. In some aspects, thestrain is an attenuatedstrain. In other aspects, the immunosuppressive target is STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, pGE2 or VEGF. In one embodiment, the immunosuppressive target is IDO1 or Arg1 and the shRNA molecule is any one of SEQ ID NO:5-14.